Smegglutide, liraglutide, and telpolide are mainstream GLP-1 class weight-loss/blood sugar-lowering drugs. Their prices vary significantly depending on brand, specifications, distribution channels, and medical insurance policies. The price range per injection is as follows: Smegglutide 1000-3000 RMB, liraglutide 400-1000 RMB, and telpolide 600-1200 RMB. Actual expenditure needs to be comprehensively assessed based on medical insurance reimbursement and long-term usage costs.
1. Smegglutide: One injection per week, long-lasting and convenient.
Market reference price: The price per vial is generally between 1000-3000 RMB, depending on the specifications (e.g., 1.5ml or 3ml), brand (imported original vs. domestic), and purchase channel.
Medical Insurance Coverage: Smegglutide (trade name "Novogene®") is included in the Category B medical insurance catalog, with reimbursement rates of 50%-70% in some cities. After deducting the cost, the average monthly expense can be reduced to approximately 500-1000 yuan.
Frequency of Use: Once a week, high compliance, suitable for long-term management.
2. Liraglutide: One injection daily, affordable price.
Market Reference Price: Price per vial is mostly between 400-800 yuan; domestic generic drugs or smaller packaging can be as low as 300 yuan.
Medical Insurance Coverage: Included in national medical insurance; for eligible patients, the deductible after reimbursement can be as low as 200-400 yuan per vial.
Frequency of Use: Requires daily injection; some patients have lower compliance due to frequent administration.
3. Telpoeptide: A rising star with dual-target effects and outstanding weight loss results
Market reference price: Approximately 600-1200 RMB per vial; high-end specifications or bundled services from private institutions can reach over 2000 RMB.
Medical insurance coverage: Currently not fully covered by medical insurance for weight loss indications; some cities offer partial reimbursement for diabetes indications, but out-of-pocket expenses remain significant.
Advantages: As a GLP-1/GIP dual receptor agonist, clinical data shows its weight loss effect is superior to the previous two, with an average weight loss of over 20 kg.